Actively Recruiting
Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT) for Schizophrenia
Led by Bristol-Myers Squibb · Updated on 2026-04-30
1500
Participants Needed
45
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are observing treatment patterns, effectiveness, and side effects in adults with schizophrenia who have started using xanomeline and trospium chloride (KarXT) in the United States. This study aims to describe real-world use and outcomes of KarXT treatment for schizophrenia based on clinical practice. Participants diagnosed with schizophrenia will receive xanomeline and trospium chloride (KarXT) as prescribed by their clinician. The study follows participants from baseline up to 20 weeks, monitoring treatment changes and switches, adverse events, weight changes, clinical improvement scores, relapse rates, treatment continuation, and reasons for stopping treatment. During the study, researchers will collect data on demographics, family history, previous treatments, and clinical outcomes. Participants will be monitored for treatment titration, adverse events, use of antiemetics for gastrointestinal symptoms, and schizophrenia-related hospital visits. Data will be gathered from baseline through 20 weeks to evaluate treatment patterns and patient experiences over this period.
CONDITIONS
Brief Title
Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants or their caregiver/legal guardian must sign a written informed consent form approved by an ethics committee.
- Adults 18 years or older at baseline willing and able to participate in routine clinical care and follow-up.
- Diagnosed with schizophrenia as confirmed by a treating clinician.
- Starting xanomeline and trospium chloride (KarXT) treatment within 16 weeks with intent to stop prior antipsychotic treatment(s), or on a stable antipsychotic regimen for at least 30 days with plan to switch to KarXT.
- Concomitant psychiatric medications are allowed if doses remain stable during the study period.
You will not qualify if you...
- Previous use of KarXT discontinued before baseline.
- Participation in another interventional study within 30 days before baseline or planned participation during the study.
- Known allergy to xanomeline or trospium chloride.
- History or high risk of urinary retention, gastric retention, moderate or severe liver impairment, or narrow-angle glaucoma.
- Unstable psychiatric or medical conditions preventing safe switch to KarXT.
- Pregnant, planning pregnancy, or breastfeeding.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 20 weeks
Participants receive xanomeline and trospium chloride (KarXT) according to their clinician's prescribing regimen and are monitored for treatment effectiveness and adverse effects.
Visits as per routine clinical care and follow-up
Trial Site Locations
Total: 45 locations
1
Local Institution - 0009
Bryant, Arkansas, United States, 72022
Not Yet Recruiting
2
Local Institution - 0003
Anaheim, California, United States, 92805
Not Yet Recruiting
3
Local Institution - 0039
Chino, California, United States, 91710
Not Yet Recruiting
4
Local Institution - 0012
La Palma, California, United States, 90623
Not Yet Recruiting
5
Local Institution - 0043
Oceanside, California, United States, 92056-4509
Not Yet Recruiting
6
Local Institution - 0028
Stanford, California, United States, 94304
Not Yet Recruiting
7
Local Institution - 0005
Bonita Springs, Florida, United States, 34134
Not Yet Recruiting
8
Local Institution - 0019
Hialeah, Florida, United States, 33016-1814
Not Yet Recruiting
9
Local Institution - 0030
Homestead, Florida, United States, 33030
Not Yet Recruiting
10
Local Institution - 0029
Kendall, Florida, United States, 33186
Not Yet Recruiting
11
Local Institution - 0032
Miami, Florida, United States, 33015
Not Yet Recruiting
12
Banyan Behavioal Care Program - CSU
Miami, Florida, United States, 33134
Actively Recruiting
13
Local Institution - 0007
Miami, Florida, United States, 33155
Not Yet Recruiting
14
Local Institution - 0006
Miami, Florida, United States, 33175
Not Yet Recruiting
15
Local Institution - 0023
Orange City, Florida, United States, 32763
Not Yet Recruiting
16
Local Institution - 0040
Orlando, Florida, United States, 32803
Not Yet Recruiting
17
Local Institution - 0025
Atlanta, Georgia, United States, 30303
Not Yet Recruiting
18
Local Institution - 0044
Marietta, Georgia, United States, 30060
Not Yet Recruiting
19
Local Institution - 0014
Bloomfield Township, Michigan, United States, 48302-1909
Not Yet Recruiting
20
Local Institution - 0036
Detroit, Michigan, United States, 48203
Not Yet Recruiting
21
Local Institution - 0034
Apple Valley, Minnesota, United States, 55124
Not Yet Recruiting
22
Local Institution - 0041
Lincoln, Nebraska, United States, 68526-9474
Not Yet Recruiting
23
Local Institution - 0037
Buffalo, New York, United States, 14215
Not Yet Recruiting
24
Local Institution - 0004
Monsey, New York, United States, 10952
Not Yet Recruiting
25
Local Institution - 0038
Rochester, New York, United States, 14623
Not Yet Recruiting
26
Local Institution - 0020
White Plains, New York, United States, 10601
Not Yet Recruiting
27
Local Institution - 0042
Cary, North Carolina, United States, 27513
Not Yet Recruiting
28
PPD Virtual - PPD - US
Wilmington, North Carolina, United States, 28401-3331
Actively Recruiting
29
Local Institution - 0031
Mason, Ohio, United States, 45040-7846
Not Yet Recruiting
30
Local Institution - 0027
Oklahoma City, Oklahoma, United States, 73112-8729
Not Yet Recruiting
31
Local Institution - 0015
Philadelphia, Pennsylvania, United States, 19104-4238
Not Yet Recruiting
32
Psychiatric Consultants, Pc
Franklin, Tennessee, United States, 37607
Actively Recruiting
33
Local Institution - 0016
Austin, Texas, United States, 78754
Not Yet Recruiting
34
Local Institution - 0021
Fort Worth, Texas, United States, 76132
Not Yet Recruiting
35
Local Institution - 0033
Houston, Texas, United States, 77007-9015
Not Yet Recruiting
36
Local Institution - 0026
Houston, Texas, United States, 77008-1758
Not Yet Recruiting
37
Local Institution - 0022
Houston, Texas, United States, 77054-2852
Not Yet Recruiting
38
Local Institution - 0010
Houston, Texas, United States, 77054
Not Yet Recruiting
39
Local Institution - 0024
Houston, Texas, United States, 77099
Not Yet Recruiting
40
Local Institution - 0017
Irving, Texas, United States, 75062-2757
Not Yet Recruiting
41
Local Institution - 0013
McKinney, Texas, United States, 75092
Not Yet Recruiting
42
Local Institution - 0008
Richmond, Texas, United States, 77407-3498
Not Yet Recruiting
43
Local Institution - 0035
San Antonio, Texas, United States, 78240
Not Yet Recruiting
44
Local Institution - 0018
Stafford, Texas, United States, 77477-3954
Not Yet Recruiting
45
Local Institution - 0045
Petersburg, Virginia, United States, 23805
Not Yet Recruiting
Research Team
B
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
F
First line of the email MUST contain NCT # and Site #.
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here